Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics expands board to 10, appoints Carolyn Starrett as director

Neutral Impact 2 of 5 leadership Written later

NeoGenomics increased its Board from nine to ten directors on June 23, 2026, and appointed Carolyn S. Starrett to fill the new seat, effective immediately. Ms. Starrett previously served as CEO of Flatiron Health and as a director of Foundation Medicine, and the filing describes her as an independent director.

Key points

  • Board size increased from nine to ten directors on June 23, 2026
  • Carolyn S. Starrett appointed director, serving until the 2027 annual meeting
  • Starrett led Flatiron Health as CEO and Board Director from April 2021 to September 2025
  • Company stated her compensation follows its director compensation program in the 2026 proxy statement

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECJun 25, 2026, 7:10 AM ET
Accession number0001628280-26-045350

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 25, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.